IL10 promotes differentiation of Tregs, enhances tumor cell survival, proliferation, and metastasis by controlling antitumor immunity mostly through the STAT3 signaling pathway via the IL10 receptor (IL10R), whereas IL6 activates Th2 cells to promote tumor progression (35). The gene discussed is IL6; the disease is neoplasm.